Induction of TNF Receptors During IL-2 Treatment
Author Information
Author(s): D.W. Miles, D. Aderka, H. Engelmann, D. Wallach, F.R. Balkwill
Primary Institution: Imperial Cancer Research Fund Clinical Oncology Unit, Guy's Hospital
Hypothesis
Does interleukin-2 treatment induce soluble tumor necrosis factor receptors in advanced cancer patients?
Conclusion
Interleukin-2 treatment leads to increased levels of soluble TNF receptors in advanced cancer patients.
Supporting Evidence
- Plasma levels of TNF in patients were not significantly different from normal controls.
- Levels of soluble TNF receptors were significantly higher in patients compared to normal controls.
- Induced levels of soluble TNF receptors correlated closely with maximum induced levels of TNF.
Takeaway
When patients with advanced cancer receive a treatment called IL-2, their bodies produce more of certain proteins that can help control inflammation.
Methodology
Plasma samples from 22 patients with metastatic carcinoma were analyzed for TNF and soluble TNF receptors before and during IL-2 treatment.
Limitations
The study did not record responses to treatment in the patient group.
Participant Demographics
Patients included 12 with breast cancer, 6 with melanoma, and 4 with renal cell carcinoma.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website